ArticleInternational journal of clinical and experimental pathology2018
TGF-β1 suppresses syndecan-2 expression through the ERK signaling pathway in nucleus pulposus cells.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration.The Journal of international medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is the main cause of low back pain and has become a worldwide problem causing enormous economic loss. Thus, mechanisms and treatment of IVDD are attracting great attention from surgeons and physicians. The syndecan (SDC) family has been reported to play important roles in various physiopathologic processes. In this study, we found that SDC2 expression levels were positively correlated with IVDD grades in human samples. Moreover, we demonstrated that transforming growth factor-β1 inhibited SDC2 expression through ERK1/2 signaling pathway activation in nucleus pulposus cells. Knocking down SDC2 in disc cells significantly suppressed aggrecanase-1 and aggrecanase-2 expression. The results of our study indicate that SDC2 may be a therapeutic target through which extracellular matrix degradation of IVDD can be controlled.
Indexed as
Identifiers
31938308PMC6958228W3028111348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.